Imaging Core

成像核心

• 批准号: 7670958
• 负责人: Mark A. Mintun
• 金额: $ 72.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7670958
• 关键词: Alzheimer' s Disease; Amyloid; Amyloid Proteins; Amyloid beta-Protein; Amyloid deposition; Anatomy; Archives; Binding; Binding Sites; Biochemical; Biological; Biological Markers; Brain; Brain Injuries; Brain imaging; Cells; Clinical; Collection; Data; Data Set; Databases; Decision Making; Dementia; Deposition; Disease; Evaluation; Functional disorder; Generations; Goals; Hand; Head; Image; Imaging Techniques; Individual; Informatics; Intervention; Late Onset Alzheimer Disease; Magnetic Resonance Imaging; Measures; Metabolic; Metabolism; Morphologic artifacts; Neuronal Dysfunction; Neurons; Noise; Participant; Positron-Emission Tomography; Procedures; Process; Protocols documentation; Psychometrics; Qualifying; Quality Control; Quarantine; Recruitment Activity; Relative (related person); Research Personnel; Resolution; Role; Scanning; Senile Plaques; Series; Signal Transduction; Site; Staging; Standardization; Standards of Weights and Measures; Testing; Time; Work; abeta accumulation; brain tissue; brain volume; density; design; glucose metabolism; gray matter; image processing; insight; interest; neuroimaging; pre-clinical; relating to nervous system

We hypothesize that Alzheimer's disease (AD) has a preclinical stage in which elevated levels of brain amyloid protein and accumulation of beta-amyloid deposits foreshadow the gradual onset of neuronal dysfunction, cell loss and dementia. While the exact role of amyloid in the initiation of brain damage is still unclear, clarifying the exact timing of amyloid deposition that precede AD would be extremely helpful in understanding the biological origins of AD and in designing appropriate interventions. Brain imaging provides a window into many of the hypothesized biochemical, functional and anatomic changes in AD. With Positron Emission Tomography (PET) using [11C]PIB it is possible to estimate the density of beta-amyloid plaques by imaging the PIB binding sites. With PET using [18F]FDG it is possible to estimate neuronal function from measures of metabolic activity. Finally, with magnetic resonance imaging (MRI) volume loss over time can be quantified in regional and global brain measures. It is our premise that by examining the temporal and spatial interrelationships between these three measures important insights will be gained in the pathophysiology of AD. The value of these imaging biomarkers are further enhanced by combining the data with CSF biomarkers and clinical and psychometric data. Towards these goals, the Imaging Core will provide two key support activities to the DIAN effort: Aim 1: Oversee the collection of all image data. This data includes MR scans for morphometrics, PET FDG scans for metabolism and PET PIB scans for imaging beta-amyloid plaques. Aim 2: Perform image processing and analysis to extract biologically relevant measures from the image data set. These measures include whole brain volume and cortical and subcortical regional measures of gray matter volume, relative glucose metabolism and PIB-derived estimates of beta-amyloid plaque deposition.

我们假设阿尔茨海默氏病（AD）有一个临床前阶段，在此阶段，大脑中的脑细胞水平升高 淀粉样蛋白和β-淀粉样沉积物的积累预示着神经元疾病的逐渐发生 功能障碍、细胞损失和痴呆。虽然淀粉样蛋白在引发脑损伤中的确切作用仍不清楚 不清楚，澄清 AD 之前淀粉样蛋白沉积的确切时间将非常有帮助 了解 AD 的生物学起源并设计适当的干预措施。脑成像提供 这是了解 AD 中许多假设的生化、功能和解剖学变化的窗口。带正电子 使用 [11C]PIB 的发射断层扫描 (PET) 可以通过以下方式估计 β-淀粉样斑块的密度： 对 PIB 结合位点进行成像。通过使用 [18F]FDG 的 PET，可以估计神经元功能 代谢活动的测量。最后，随着时间的推移，磁共振成像 (MRI) 的体积损失可以 通过区域和全球大脑测量进行量化。我们的前提是，通过检查时间和 这三个指标之间的空间相互关系将在以下过程中获得重要见解： AD 的病理生理学。 通过将数据与脑脊液生物标志物相结合，这些成像生物标志物的价值进一步增强 以及临床和心理测量数据。为了实现这些目标，成像核心将提供两个关键支持 DIAN 的活动： 目标 1：监督所有图像数据的收集。该数据包括 MR 扫描 对于形态测量，PET FDG 扫描用于代谢，PET PIB 扫描用于 β-淀粉样斑块成像。 目标 2：执行图像处理和分析，从图像数据中提取生物学相关的测量值 放。这些测量包括全脑容量以及皮质和皮质下区域的灰色测量 物质体积、相对葡萄糖代谢和 PIB 衍生的 β-淀粉样斑块沉积估计。